Lacosamide Accord

Lacosamide, the active ingredient in Lacosamide Accord, is an anti‑epileptic presented as an intravenous solution for intravenous use. It treats partial‑onset seizures and can be used for acute seizure management in patients requiring hospital care.

GNH USA supplies Lacosamide Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anti‑epileptic drug indicated for several seizure‑related conditions.

Partial‑onset seizures: adjunctive therapy to reduce seizure frequency in patients already on antiepileptic regimens. Acute seizure treatment: rapid intravenous control of seizure activity in emergency or peri‑operative settings. Status epilepticus (adjunct): may be considered as an additional option for refractory status epilepticus when standard therapies are insufficient.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: increased tiredness or lack of energy. - Nausea: feeling of stomach upset or urge to vomit. - Headache: mild to moderate cranial pain. - Blurred vision: temporary visual disturbances. - Diplopia: double vision in some patients.

Serious or Rare Side Effects: - Cardiac arrhythmias: including atrial fibrillation or prolonged PR interval. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal ideation: emergence of thoughts of self‑harm. - Respiratory depression: especially when combined with other CNS depressants. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Anaphylaxis: rare but potentially life‑threatening allergic response.

When using Lacosamide, clinicians should observe several safety measures.

Monitor cardiac function: obtain baseline ECG and watch for PR‑interval changes. Assess renal function: adjust dosing in patients with impaired clearance. Avoid abrupt discontinuation: taper to prevent seizure exacerbation. Use caution in hepatic impairment: monitor liver enzymes regularly. Pregnancy: risk unknown; weigh potential benefits against risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lacosamide can interact with various medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concomitant sodium channel blockers (e.g., carbamazepine): may increase neurotoxicity. - Strong CYP3A4 inducers (e.g., rifampin): can markedly reduce lacosamide plasma levels. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise lacosamide concentrations and risk toxicity.

Moderate Interactions (Monitor Closely): - Other antiepileptic drugs (e.g., valproate): may alter efficacy or side‑effect profile. - Warfarin: potential increase in INR, requiring closer coagulation monitoring. - Alcohol: may enhance central nervous system depression, increasing dizziness or sedation.